Ticker Details
Exelixis, Inc. Common Stock Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
IPO Date:	May 1, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$14.35B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.31 | 2.46%
Avg Daily Range (30 D):	$1.00 | 1.91%
Avg Daily Range (90 D):	$0.94 | 2.00%

Institutional Daily Volume
Avg Daily Volume:	2.07M
Avg Daily Volume (30 D):	1.75M
Avg Daily Volume (90 D):	2.03M

Trade Size
Avg Trade Size (Sh.):	151
Avg Trade Size (Sh.) (30 D):	53
Avg Trade Size (Sh.) (90 D):	56

Institutional Trades
Total Institutional Trades:	13,014
Avg Institutional Trade:	$3.17M
Avg Institutional Trade (30 D):	$8.56M
Avg Institutional Trade (90 D):	$6.87M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$7.95M
Avg Closing Trade (30 D):	$40.67M
Avg Closing Trade (90 D):	$28.98M
Avg Closing Volume:	341.77K

News

Jun 10, 2026 @ 5:00 PM Metastatic Prostate Cancer Market Set for Robust G... Source: Delveinsight

May 15, 2026 @ 11:30 PM Prediction: This Stock Could Double By 2031 Source: Prosper Junior Bakiny

Apr 21, 2026 @ 5:42 PM Why Is Merck Stock Falling Tuesday? Source: Vandana Singh

Mar 18, 2026 @ 12:30 PM The Best Healthcare Stocks to Buy With $50 Right N... Source: Prosper Junior Bakiny

Feb 28, 2026 @ 9:37 AM 3 Reasons Exelixis Stock Could Deliver Marketâ€... Source: James Halley

Financials
	TTM	Q1 2027	Q3 2026
Basic EPS		$.81	$.72
Diluted EPS		$.79	$.69
Revenue		$610.81M	$597.76M
Gross Profit		$590.86M	$579.18M
Net Income / Loss		$210.47M	$193.58M
Operating Income / Loss		$251.34M	$236.54M
Cost of Revenue		$19.95M	$18.57M
Net Cash Flow		$-256.34M	$211.87M
PE Ratio